Havent been updated with the melanoma trial with keytruda/ MSD but the following
Phase I/II clinical trial (QBC46-H03) evaluating the optimal dose of our lead oncology molecule tigilanol tiglate in patients with head and neck squamous cell carcinoma (HNSCC)
cheers
- Forums
- ASX - By Stock
- Qbiotics
Qbiotics, page-768
-
- There are more pages in this discussion • 473 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online